Alcon Inc. (ETR:2U3)
Germany · Delayed Price · Currency is EUR | Market Cap | 27.32B -12.9% |
| Revenue (ttm) | 9.51B +8.3% |
| Net Income | 562.82M -40.1% |
| EPS | 1.15 -39.2% |
| Shares Out | n/a |
| PE Ratio | 48.55 |
| Forward PE | 15.68 |
| Dividend | 0.31 (0.54%) |
| Ex-Dividend Date | May 5, 2026 |
| Volume | 1,949 |
| Open | 56.66 |
| Previous Close | 56.64 |
| Day's Range | 56.42 - 57.28 |
| 52-Week Range | 52.42 - 74.62 |
| Beta | 0.70 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 11, 2026 |
About Alcon
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS... [Read more]
Financial Performance
In 2025, Alcon's revenue was $10.40 billion, an increase of 4.94% compared to the previous year's $9.91 billion. Earnings were $980.00 million, a decrease of -3.73%.
Financial numbers in USD Financial StatementsNews
Introducing Systane PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief
Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of Systane PRO Preservative-Free (PF) in Canada as Systane’s most advanced formula. Systane...
Alcon Becomes Oversold (ALC)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Alcon price target lowered to $85 from $95 at Jefferies
Jefferies analyst Michael Sarcone lowered the firm’s price target on Alcon (ALC) to $85 from $95 and keeps a Buy rating on the shares. The ophthalmology sector has been under…
Alcon announces initial commercial launch of UNITY M
Alcon (ALC) announced the initial commercial launch of UNITY M, an Alcon brand premium surgical microscope that delivers precise control to ophthalmic surgeons, in select markets including the U.S. an...
Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control
GENEVA--(BUSINESS WIRE)--Alcon Launches UNITY® M, a Premium Ophthalmic Microscope Delivering Precise Control.
Platauro Metals Corp. - Star Project, Utah
Vancouver, British Columbia--(Newsfile Corp. - September 2, 2026) - Platauro Metals Corp. (TSXV: PURO) (OTCQB: MEXGF) ("Platauro" or the "Company") announces that its wholly-owned subsidiary, Alcon Si...
Alcon Prices EUR 500 Million Senior Notes Offering
GENEVA--(BUSINESS WIRE)--Alcon Prices EUR 500 Million Senior Notes Offering.
Alcon’s Q2 2026 Growth Shows UNITY Momentum, but Cataract Softness and Implantables Competition Still Matter
What the latest reported quarter says about the current operating story and the main business drivers Alcon Inc. (NYSE: ALC)... The post Alcon’s Q2 2026 Growth Shows UNITY Momentum, but Cataract Softn...
Alcon (ALC) Q2 2026 Earnings Call Transcript
Net sales grew 7% to $2.8 billion as surgical and vision care divisions both expanded.
Alcon price target raised to CHF 73 from CHF 70 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Alcon (ALC) to CHF 73 from CHF 70 and keeps a Buy rating on the shares.
Alcon price target raised to $78.40 from $77.53 at JPMorgan
JPMorgan raised the firm’s price target on Alcon (ALC) to $78.40 from $77.53 and keeps a Neutral rating on the shares. The firm says the company is confident that its…
Alcon price target raised to $78.40 from $77.53 at JPMorgan
JPMorgan raised the firm’s price target on Alcon (ALC) to $78.40 from $77.53 and keeps a Neutral rating on the shares. The firm says the company is confident that its…
Alcon price target raised to $85 from $80 at Mizuho
Mizuho analyst Anthony Petrone raised the firm’s price target on Alcon (ALC) to $85 from $80 and keeps an Outperform rating on the shares post the Q2 report. The firm…
Alcon price target raised to CHF 63.50 from CHF 62.80 at JPMorgan
JPMorgan raised the firm’s price target on Alcon (ALC) to CHF 63.50 from CHF 62.80 and keeps a Neutral rating on the shares.
Alcon downgraded to Neutral from Outperform at BNP Paribas
BNP Paribas downgraded Alcon (ALC) to Neutral from Outperform with a $79 price target The firm sees a challenged outlook for the company in the second half of 2026 and…
Mining company rapidly acquiring village land, allege Surla locals
Surla village gram sabha in Goa saw heated debate over Alcon cement factory pollution, worker regularisation, and alleged large-scale land purchases by a mining company.
Bill Ackman Unveils Six New Investments In Major Portfolio Overhaul
WASHINGTON (dpa-AFX) - Billionaire investor Bill Ackman has added six new holdings to his investment portfolio, including Netflix, Visa, Mastercard, Alcon, Intercontinental Exchange and S&P Global...
Bill Ackman Moves Stocks. These 5 Prove It.
Netflix, Visa and other stocks rose on the news that Bill Ackman was investing in them. The billionaire focuses on buying what he views as high-quality growth companies.
Bill Ackman once exited Netflix stake in a huff. Why he's buying the streaming giant again as well as these five stocks.
Netflix is once again an apple in Bill Ackman's eye, as the streamer was among six stocks Pershing Square added in the last six months.
RxSight (RXST) Q2 2026 Earnings Call Transcript
Alcon partnership revenue offsets 19% product sales decline from competitive pressure.
Alcon Stock Jumps 4% as Tariff Relief Lifts Profit Target
Alcon Stock Jumps 4% as Tariff Relief Lifts Profit Target
Alcon Releases Q2 2026 Financial Results
Alcon Inc. The post Alcon Releases Q2 2026 Financial Results first appeared on Alphastreet .
Alcon Earnings Call Transcript: Q2 2026
Q2 2026 saw 7% sales growth, driven by strong adoption of UNITY equipment, PanOptix Pro IOL, and robust contact lens and ocular health performance. Core margins and EPS improved, with guidance reaffirmed for 5%-7% sales growth and 12%-15% EPS growth. Key launches and innovation are expected to sustain momentum.
Alcon Quarterly report: Q2 2026
Alcon has published its Q2 2026 quarterly earnings report on August 11, 2026.
Alcon Earnings release: Q2 2026
Alcon released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.